Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to -$1.6 billion.

  • Arrowhead Pharmaceuticals' Retained Earnings rose 1124.56% to -$1.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$1.6 billion, marking a year-over-year increase of 1124.56%. This contributed to the annual value of -$1.6 billion for FY2025, which is 10.03% down from last year.
  • As of Q4 2025, Arrowhead Pharmaceuticals' Retained Earnings stood at -$1.6 billion, which was up 1124.56% from -$1.6 billion recorded in Q3 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' Retained Earnings registered a high of -$551.4 million during Q1 2021, and its lowest value of -$1.8 billion during Q4 2024.
  • Over the past 5 years, Arrowhead Pharmaceuticals' median Retained Earnings value was -$971.2 million (recorded in 2023), while the average stood at -$1.1 billion.
  • As far as peak fluctuations go, Arrowhead Pharmaceuticals' Retained Earnings tumbled by 5878.05% in 2024, and later soared by 1124.56% in 2025.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Retained Earnings (Quarter) stood at -$707.6 million in 2021, then dropped by 21.84% to -$862.1 million in 2022, then plummeted by 34.43% to -$1.2 billion in 2023, then plummeted by 55.2% to -$1.8 billion in 2024, then increased by 11.25% to -$1.6 billion in 2025.
  • Its Retained Earnings stands at -$1.6 billion for Q4 2025, versus -$1.6 billion for Q3 2025 and -$1.6 billion for Q2 2025.